{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T08:45:31Z","timestamp":1777020331898,"version":"3.51.4"},"reference-count":107,"publisher":"Informa UK Limited","issue":"5","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2026,3,24]]},"DOI":"10.1080\/14656566.2026.2654676","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T08:05:41Z","timestamp":1775117141000},"page":"423-437","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Role of novel \u03b2-lactam antibiotics in the treatment of bacterial pneumonia"],"prefix":"10.1080","volume":"27","author":[{"given":"Susanna","family":"Esposito","sequence":"first","affiliation":[{"name":"University Hospital of Parma","place":["Parma, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Principi","sequence":"additional","affiliation":[{"name":"Universit\u00e0 degli Studi di Milano","place":["Milan, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2026,4,7]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare11131946"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01867-1"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics14101006"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu013"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9010275"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50805-z"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.2217\/fmb.11.18"},{"key":"e_1_3_4_10_1","volume-title":"Beta-lactam antibiotics","author":"Pandey N","year":"2025","unstructured":"Pandey N, Cascella M. Beta-lactam antibiotics. Treasure Island (FL): StatPearls Publishing; 2025 Jan. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK545311\/"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a025247"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/pro.3737"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mib.2021.01.008"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s000180050160"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01076-18"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1012902"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-018-0048-6"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.4103\/ijmr.IJMR_2079_17"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(24)00176-2"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw504"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000441-196509000-00003"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.1995.1.115"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.micres.2022.127221"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01644-07"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-78538-7_2"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/15.1.99"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.7189\/jogh.12.10004"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/MCP.0b013e32835f27be"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2012.01.003"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid0702.010204"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01009-09"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI18535"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.279.8.593"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2017.22.44.16-00696"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.b23-00685"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1556\/1886.2025.00050"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.4.1276-1281.2006"},{"key":"e_1_3_4_38_1","unstructured":"European Centre for Disease Prevention and Control. Healthcare-associated infections acquired in intensive care units - annual epidemiological report for 2020. [cited 2026 Jan 1]. Available from: https:\/\/www.ecdc.europa.eu\/en\/publications-data\/healthcare-associated-infections-acquired-intensive-care-units-annual"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy543"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-016-2703-z"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiph.2019.01.057"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/10.4.867"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1469-0691.2000.00107.x"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-024-02102-8"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.24171\/j.phrp.2022.0323"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms11071690"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/s43856-024-00591-y"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201908-1581ST"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1086\/657313"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000001159"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40801-024-00422-5"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04068-14"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2013.01.005"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0117-2023"},{"issue":"1","key":"e_1_3_4_55_1","article-title":"P-1360. Restoring efficacy against ceftaroline-resistant MRSA with ceftaroline-carbapenem combinations","volume":"13","author":"Olso JA","year":"2026","unstructured":"Olso JA, Alaguvel V, P\u00e9rez-Parra G, et al. P-1360. Restoring efficacy against ceftaroline-resistant MRSA with ceftaroline-carbapenem combinations. Open Forum Infect Dis. 2026;13(1):ofaf695.1547.","journal-title":"Open Forum Infect Dis"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2025.116838"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms12040725"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2011.11.005"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu219"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000003077"},{"issue":"3","key":"e_1_3_4_61_1","first-page":"11","article-title":"Ceftobiprole: pharmacokinetics and PK\/PD profile","volume":"32","author":"Azanza Perea JR","year":"2019","unstructured":"Azanza Perea JR, S\u00e1daba D\u00edaz de Rada B. Ceftobiprole: pharmacokinetics and PK\/PD profile. Rev Esp Quimioter. 2019;32 Suppl 3(Suppl 3):11\u201316.","journal-title":"Rev Esp Quimioter"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.37201\/req\/s02.02.2022"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms11040984"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.106825"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000004347"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30796-9"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30731-3"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlad085"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkac221"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2025.1670179"},{"key":"e_1_3_4_71_1","unstructured":"European Medicine Agency. Fetcroja INN-cefiderocol. [cited 2026 Jan 1]. Available from: http\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/ec.europa.eu\/health\/documents\/community-register\/2020\/20200423147625\/anx_147625_en.pdf"},{"key":"e_1_3_4_72_1","unstructured":"Drugs.com Fetroja FDA Approval History. [cited 2026 Jan 1]. Available from: html#:~:text=FDA%20Approved:%20Yes%20(First%20approved CNS)%20adverse%20reactions%20including%20seizures"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.1035609"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00834-09"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa278"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13613-022-01084-8"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00405-23"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00569-25"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03057-14"},{"key":"e_1_3_4_80_1","first-page":"e70234","article-title":"Real-world evidence on use of ceftazidime-avibactam in the management of Gram-negative infections: a retrospective analysis","volume":"16","author":"Todi S","year":"2024","unstructured":"Todi S, Sathe P, Rao PV, et al. Real-world evidence on use of ceftazidime-avibactam in the management of Gram-negative infections: a retrospective analysis. Cureus. 2024;16:e70234.","journal-title":"Cureus"},{"key":"e_1_3_4_81_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkac049"},{"key":"e_1_3_4_82_1","unstructured":"European Medicine Agency. Zavicepta. [cited 2026 Jan 1]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zavicefta"},{"key":"e_1_3_4_83_1","unstructured":"Food and Drug Administration. AVYCAZ. [cited 2026 Jan 1]. Available from: http:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/206494s012lbl.pdf"},{"key":"e_1_3_4_84_1","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2025.30.14.2400399"},{"key":"e_1_3_4_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2024.04.014"},{"key":"e_1_3_4_86_1","unstructured":"European Mdicines Agency. Exblifep. [cited 2026 Jan 1]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/exblifep#:~:text=Recommendations%20and%20precautions%20to%20be EU%20on%2021%20March%202024"},{"key":"e_1_3_4_87_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-198631020-00002"},{"key":"e_1_3_4_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(24)00561-9"},{"key":"e_1_3_4_89_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01224-17"},{"key":"e_1_3_4_90_1","doi-asserted-by":"crossref","first-page":"e0154823","DOI":"10.1128\/aac.01548-23","article-title":"Effect of modification of penicillin-binding protein 3 on susceptibility to ceftazidime-avibactam, imipenem-relebactam, meropenem-vaborbactam, aztreonam-avibactam, cefepime-taniborbactam, and cefiderocol of Escherichia coli strains producing broad-spectrum \u03b2-lactamases","volume":"68","author":"Le Terrier C","year":"2024","unstructured":"Le Terrier C, Nordmann P, Buchs C, et al. Effect of modification of penicillin-binding protein 3 on susceptibility to ceftazidime-avibactam, imipenem-relebactam, meropenem-vaborbactam, aztreonam-avibactam, cefepime-taniborbactam, and cefiderocol of Escherichia coli strains producing broad-spectrum \u03b2-lactamases. Antimicrob Agents Chemother. 2024;68:e0154823.","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_4_91_1","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens13030197"},{"key":"e_1_3_4_92_1","unstructured":"Pfizer Inc. Summary of product characteristics: emblaveo 1.5 g\/0.5 g powder for concentrate for solution for infusion. [cited 2026 Jan 1]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/emblaveo-epar-product-information_en.pdf"},{"key":"e_1_3_4_93_1","unstructured":"AbbVie. EMBLAVEO (aztreonam and avibactam) for injection for intravenous use. [cited 2026 Jan 1]. Available from: https:\/\/www.rxabbvie.com\/pdf\/emblaveo_pi.pdf"},{"key":"e_1_3_4_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(24)00499-7"},{"key":"e_1_3_4_95_1","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlaf131"},{"key":"e_1_3_4_96_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01935-19"},{"key":"e_1_3_4_97_1","unstructured":"European Medicines Agency Vaborem. [cited 2026 Jan 1]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vaborem"},{"key":"e_1_3_4_98_1","unstructured":"Drugs.com. FDA approves vabomere. [cited 2026 Jan 1]. Available from: https:\/\/www.drugs.com\/newdrugs\/fda-approves-vabomere-meropenem-vaborbactam-complicated-urinary-tract-infections-4587.html"},{"key":"e_1_3_4_99_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.16145"},{"key":"e_1_3_4_100_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25179574"},{"key":"e_1_3_4_101_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-021-01375-0"},{"key":"e_1_3_4_102_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02406-17"},{"key":"e_1_3_4_103_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12866-019-1522-7"},{"key":"e_1_3_4_104_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01471-8"},{"key":"e_1_3_4_105_1","unstructured":"Merck Sharp & Dohme. Recarbrio: EU summary of product characteristics. 2021 [cited 2026 Jan 1]. Available from: https:\/\/www.ema.europa.eu"},{"key":"e_1_3_4_106_1","unstructured":"Merck Sharp & Dohme. Recarbrio\u2122 (imipenem cilastatin and relebactam): US prescribing information. 2020 [cited 2026 Jan 1]. Available from: https:\/\/www.fda.gov"},{"key":"e_1_3_4_107_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz530"},{"key":"e_1_3_4_108_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa803"},{"key":"e_1_3_4_109_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.2334"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2026.2654676","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T08:02:34Z","timestamp":1777017754000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2026.2654676"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":107,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,3,24]]}},"alternative-id":["10.1080\/14656566.2026.2654676"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2026.2654676","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-02-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}